Skip to main
SNDX

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Syndax Pharmaceuticals (SNDX) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Syndax Pharmaceuticals is a promising biopharmaceutical company with a strong pipeline of drugs targeting multiple cancer indications and other diseases. The company's recent positive data in both pre-clinical and clinical studies demonstrate its potential for success in the future. However, investors should still consider the potential risks associated with drug development and competition in the market when evaluating this stock.

Bears say

Syndax Pharmaceuticals is currently facing multiple challenges that could negatively impact its stock. These include the early stages of its product candidates, the competition in the biopharmaceutical industry, and the high financial risk associated with clinical trials and drug development. Additionally, the company faces uncertainty in its ability to successfully develop and commercialize its products, as well as potential resistance mutations and competition from other menin inhibitors. Its current financials also raise concerns, with limited revenue and significant expenses for research and development.

Syndax Pharmaceuticals (SNDX) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Syndax Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Syndax Pharmaceuticals (SNDX) Forecast

Analysts have given Syndax Pharmaceuticals (SNDX) a Strong Buy based on their latest research and market trends.

According to 11 analysts, Syndax Pharmaceuticals (SNDX) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Syndax Pharmaceuticals (SNDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.